Previous close | 2.9500 |
Open | N/A |
Bid | 2.4000 |
Ask | 2.8500 |
Strike | 5.00 |
Expiry date | 2024-09-20 |
Day's range | 2.9500 - 2.9500 |
Contract range | N/A |
Volume | |
Open interest | 20 |
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.